Hyperaldosteronism
·MeSH: Hyperaldosteronism
Prevalence
0.1 / 100K
1 drug in development·1 company·2 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| baxdrostat | ASTRAZENECA PLC (AZN) |
Frequently asked questions
How many drugs are in development for Hyperaldosteronism?
BioSniper tracks 1 drug in development for Hyperaldosteronism across 1 company.
How many clinical trials target Hyperaldosteronism?
There are 2 clinical trials targeting Hyperaldosteronism tracked by BioSniper.
What is the prevalence of Hyperaldosteronism?
The estimated prevalence of Hyperaldosteronism is approximately 0.1 per 100,000 population.
Deep-dive into Hyperaldosteronism
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis